Placeholder Banner

BIO Comments on FDA Draft Guidance on Nonproprietary Naming of Biological Products: Update

May 3, 2019

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Nonproprietary Naming of Biological Products: Update.

BIO is committed to improving access to safe, effective, and affordable therapeutic choices, including biosimilars, which require policies distinct from policies for generic small molecule drugs. As more biosimilars and interchangeable biosimilars become available in the United States, it’s critically important to be able to accurately identify these products.

In the comments, BIO explains the importance of distinguishable, nonproprietary names and a nonproprietary naming convention for biologics. BIO was pleased FDA included the use of a four-letter distinguishable suffix for biologics. BIO provides additional input on a potential naming convention as well as whether vaccines should be included in the scope.

Download Full Comments Below
FINAL BIO Comment Nonproprietary Naming 5-3-19
Please see below to read full comment letter
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…